Efficacy and Safety of Relamorelin in Diabetics With Symptoms of Gastroparesis: A Randomized, Placebo-Controlled Study
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Background & Aims Gastroparesis is a complication of diabetes with few treatment options. Relamorelin (also called RM-131) is a selective, prokinetic agonist of ghrelin. We aimed to evaluate efficacy of relamorelin on symptoms and gastric emptying (GE) in a 12-week, phase 2B study of diabetic patients with moderate to severe gastroparesis symptoms (DG). Methods We performed a study of 393 patients with DG (37.7% male; 9.9% with type 1 diabetes; median age, 58.2 years [range 20–76]; median body mass index, 31.4 kg/m2 [range, 18.2–60.1]; HbA1c level, 7.6%, [range, 5.2–11.0]). All participants had 13C-spirulina GE breath test T1/2 values of 79 min or more (with 89.8% delayed relative to 90th %ile of normal, 85.75 minutes), recent vomiting, and gastroparesis cardinal symptom index-daily diary scores of 2.6 or more. Patients were randomly assigned to groups given placebo (n=104) or relamorelin (10 μg [n=98], 30 μg [n=109], or 100 μg [n=82] twice daily) for 12 weeks, following a 2-week, single-blind, placebo run-in period. Patient-reported outcomes were determined from DG Symptom Severity daily e-diaries, in which patients recorded vomiting frequency and symptom scores (nausea, abdominal pain, postprandial fullness, and bloating) on a 0–10 scale. Endpoints were change from baseline in vomiting frequency, composite DG Symptom Severity score, GE, and safety. We performed longitudinal, mixed-effects model analysis using repeated measures, with baseline and baseline-by-week interaction values as covariates. Results Patients given relamorelin had a 75% reduction in vomiting frequency compared to baseline, but this difference was not significant compared with the placebo group. All 4 symptoms of DG (composite or individual symptoms) were significantly reduced over the 12-week study period in all 3 relamorelin dose groups, compared to the placebo group (all P<.05, based on longitudinal analysis over 12 weeks). Relamorelin significantly accelerated GE from baseline compared with placebo (by 12%, P<.05 for the 10 and 30 μg groups; P=.051 for the 100 μg group). Dose-related worsening of glycemic control was noted in 14.5% of patients who received relamorelin; some required insulin or other diabetes drug dosage adjustments. Conclusions In a phase 2B randomized trial of patients with moderate to severe DG, relamorelin significantly reduced core symptoms of DG and overall composite score compared to placebo, accelerated GE, and was generally safe and well tolerated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical Guideline: Management of Gastroparesis
Camilleri, M., Parkman, H. P., Shafi, M. A., Abell, T. L., & Gerson, L. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.373 · Cited by 1,149
Self-citationBytzer, P., Talley, N. J., Leemon, M., Young, L. J., Jones, M. P., & Horowitz, M. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.16.1989 · Cited by 632 · cited 1×
“Symptoms were rated by the patients using the choic es: none (0), very mild (1), mild (2), moderate (3), severe (4), and very severe (5).”
MethodJung, H., Choung, R. S., Locke, G. R., Schleck, C. D., Zinsmeister, A. R., Szarka, L. A., Mullan, B., & Talley, N. J. (2009) · Gastroenterology · doi:10.1053/j.gastro.2008.12.047 · Cited by 571
Rentz, A. M., Kahrilas, P., Stanghellini, V., Tack, J., Talley, N. J., De la loge, C., Trudeau, E., Dubois, D., & Revicki, D. A. (2004) · Quality of Life Research · doi:10.1007/s11136-004-9567-x · Cited by 406
Self-citationAbell, T. L., Bernstein, V. K., Cutts, T., Farrugia, G., Forster, J., Hasler, W. L., Mccallum, R. W., Olden, K. W., Parkman, H. P., Parrish, C. R., et al. (2006) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2006.00760.x · Cited by 361 · cited 1×
“Symptoms were rated by the patients using the choic es: none (0), very mild (1), mild (2), moderate (3), severe (4), and very severe (5).”
MethodSelf-citationGastrointestinal tract symptoms among persons with diabetes mellitus in the community
Maleki, D., Locke, G. R., Camilleri, M., Zinsmeister, A. R., Yawn, B. P., Leibson, C., & Melton, L. J. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.18.2808 · Cited by 282
Self-citationGastric emptying and glycaemia in health and diabetes mellitus
Phillips, L. K., Deane, A. M., Jones, K. L., Rayner, C. K., & Horowitz, M. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.202 · Cited by 273
Risk of gastroparesis in subjects with type 1 and 2 diabetes in the general population
Choung, R. S., Locke, R. G., Schleck, C. D., Zinsmeister, A. R., Melton, J. L., & Talley, N. J. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.310 · Cited by 266
Szarka, L. A., Camilleri, M., Vella, A., Burton, D., Baxter, K., Simonson, J., & Zinsmeister, A. R. (2008) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.01.009 · Cited by 209
Self-citationSimilarities and differences between diabetic and idiopathic gastroparesis
Parkman, H. P., Yates, K., Hasler, W. L., Nguyen, L., Pasricha, P. J., Snape, W. J., Farrugia, G., Koch, K. L., Calles, J., Abell, T. L., et al. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.08.013 · Cited by 205
Self-citation
Cited by
Ford, A. C., Mahadeva, S., Carbone, M. F., Lacy, B. E., & Talley, N. J. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30469-4 · Cited by 517
Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines
Xiao, W., Jiang, W., Chen, Z., Huang, Y., Mao, J., Zheng, W., Hu, Y., & Shi, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02107-5 · Cited by 449
Camilleri, M., Chedid, V., Ford, A. C., Haruma, K., Horowitz, M., Jones, K. L., Low, P. A., Park, S.-Y., Parkman, H. P., & Stanghellini, V. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0038-z · Cited by 411
Self-citationACG Clinical Guideline: Gastroparesis
Camilleri, M., Kuo, B., Nguyen, L., Vaughn, V. M., Petrey, J., Greer, K., Yadlapati, R., & Abell, T. L. (2022) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001874 · Cited by 332
Self-citationGastroparesis: a turning point in understanding and treatment
Grover, M., Farrugia, G., & Stanghellini, V. (2019) · Gut · doi:10.1136/gutjnl-2019-318712 · Cited by 256
Metadata
- Authors
- Camilleri, M., McCallum, R. W., Tack, J., Spence, S. C., Gottesdiener, K., & Fiedorek, F. T.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2017-11
- Volume
- 153
- Issue
- 5
- Pages
- 1240-1250.e2
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W2741934003
- Cited by
- 157
- References
- 12
- FWCI
- 14.53
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and Safety of Relamorelin in Diabetics With Symptoms of Gastroparesis: A Randomized, Placebo-Controlled Study. https://app.cochat.ai/papers/10.1053/j.gastro.2017.07.035
- The paper
- Camilleri, M., McCallum, R. W., Tack, J., Spence, S. C., Gottesdiener, K., & Fiedorek, F. T. (2017). Efficacy and Safety of Relamorelin in Diabetics With Symptoms of Gastroparesis: A Randomized, Placebo-Controlled Study. Gastroenterology. https://doi.org/10.1053/j.gastro.2017.07.035
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.